In July 2015, Horizon Pharma, one of the world's largest specialty pharmaceutical companies, said it would buy Kalyx Pharmaceuticals in a deal valued at up to $705 million to boost its pipeline. Kalyx specializes in injectable pharmaceuticals focused on treating pain, and Horizon made the acquisition in the same field of pain management.With some $3.7 billion in net sales in 2013, Horizon makes treatments for respiratory diseases and inflammation, along with drugs for diabetes, psoriasis and other ailments.Two days later, Horizon's CEO and chairman, Paul Hoerst, said in a statement, "With Kalyx's high level of focus on manufacturing and drug delivery, I am excited to integrate the two organizations to expand our pipeline, fill out our offerings and enhance our offerings."